» Articles » PMID: 16280471

Left Ventricular Geometry in Children with Mild to Moderate Chronic Renal Insufficiency

Overview
Specialty Nephrology
Date 2005 Nov 11
PMID 16280471
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Left ventricular hypertrophy (LVH) is the most important independent marker of cardiovascular risk in adults with chronic kidney disease. Cardiovascular morbidity seems increased even in children with chronic renal insufficiency (CRI), but the age and stage of CRI when cardiac alterations become manifest are unknown. For assessing the prevalence and factors associated with abnormal LV geometry in children with CRI, echocardiograms, ambulatory BP monitoring, and biochemical profiles were obtained in 156 children aged 3 to 18 yr with stages 2 through 4 chronic kidney disease (GFR 49 +/- 19 ml/min per 1.73 m2) and compared with echocardiograms obtained in 133 healthy children of comparable age and gender. LV mass was indexed to height2.7. Concentric LV remodeling was observed in 10.2%, concentric LVH in 12.1%, and eccentric LVH in 21% of patients. LVH was more common in boys (43.3 versus 19.4%; P < 0.005). Probability of LVH independently increased with male gender (odds ratio [OR] 2.62; P < 0.05) and standardized body mass index (OR 1.56; P = 0.01). Low hemoglobin, low GFR, young age, and high body mass index were independent correlates of LV mass index (0.005 < P < 0.05). LV concentricity (relative wall thickness) was positively associated with serum albumin (P < 0.05). Probability of abnormal LV geometry increased with C-reactive protein >10 mg/dl (OR 26; P < 0.001). In conclusion, substantial cardiac remodeling of both concentric and eccentric type is present at young age and early stages of CRI in children. Prevalence of LVH is related to male gender, anemia, and ponderosity but not to BP. Additional effects of volume status and inflammation on cardiac geometry are also evident.

Citing Articles

The association between systolic and diastolic dysfunction and autonomic nervous system function in children receiving chronic hemodialysis.

Elaziz O, Ahmad G, Elgawad S, Elhady F, Hamdy R Pediatr Nephrol. 2025; .

PMID: 39873803 DOI: 10.1007/s00467-024-06577-1.


Investigation of a targeted panel of gut microbiome-derived toxins in children with chronic kidney disease.

Ebrahimi M, Hooper S, Mitsnefes M, Vasan R, Kimmel P, Warady B Pediatr Nephrol. 2025; .

PMID: 39820505 DOI: 10.1007/s00467-024-06580-6.


Hypertension monitoring on cardiac health outcomes.

Subhash S, Satariano M, Doshi K, Bhatt G, Raina R Transl Pediatr. 2024; 13(3):518-524.

PMID: 38590375 PMC: 10998995. DOI: 10.21037/tp-23-527.


Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis.

Tian L, Wang M, Liu M, Pang Y, Zhao J, Zheng B Ren Fail. 2024; 46(1):2313864.

PMID: 38345037 PMC: 10863523. DOI: 10.1080/0886022X.2024.2313864.


Electrocardiographic measurements in children with pre-dialysis chronic kidney disease and undergoing kidney replacement therapy.

Leventoglu E, Buyukkaragoz B, Kavas F, Hologlu M, Kavgaci A, Fidan K Eur J Pediatr. 2023; 182(11):4993-5005.

PMID: 37624446 DOI: 10.1007/s00431-023-05154-2.